AU2001216038A1 - Treatment of glaucoma and ocular hypertension - Google Patents

Treatment of glaucoma and ocular hypertension

Info

Publication number
AU2001216038A1
AU2001216038A1 AU2001216038A AU1603801A AU2001216038A1 AU 2001216038 A1 AU2001216038 A1 AU 2001216038A1 AU 2001216038 A AU2001216038 A AU 2001216038A AU 1603801 A AU1603801 A AU 1603801A AU 2001216038 A1 AU2001216038 A1 AU 2001216038A1
Authority
AU
Australia
Prior art keywords
glaucoma
treatment
ocular hypertension
ocular
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001216038A
Inventor
Abbot F. Clark
Raymond E Conrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of AU2001216038A1 publication Critical patent/AU2001216038A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
AU2001216038A 2000-11-14 2000-11-14 Treatment of glaucoma and ocular hypertension Abandoned AU2001216038A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/031151 WO2002040018A1 (en) 2000-11-14 2000-11-14 Treatment of glaucoma and ocular hypertension

Publications (1)

Publication Number Publication Date
AU2001216038A1 true AU2001216038A1 (en) 2002-05-27

Family

ID=21741993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001216038A Abandoned AU2001216038A1 (en) 2000-11-14 2000-11-14 Treatment of glaucoma and ocular hypertension

Country Status (2)

Country Link
AU (1) AU2001216038A1 (en)
WO (1) WO2002040018A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US6051573A (en) * 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
CO4960662A1 (en) * 1997-08-28 2000-09-25 Novartis Ag CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES
GB9816935D0 (en) * 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders

Also Published As

Publication number Publication date
WO2002040018A1 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
AU7339800A (en) Ophthalmic device and method of manufacture and use
AU2003223224A1 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
AU2002305400A1 (en) Medical device and methods of use for glaucoma treatment
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
AU2001243219A1 (en) Methods of prevention and treatment of asthma, and allergic conditions
AU7907300A (en) Novel combination of loteprednol and antihistamines
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
AU2002240463A1 (en) Use of endostatin in the treatment of ocular neovascularization
AUPQ622600A0 (en) Treatment and/or prevention of ocular pain
AU2001259085A1 (en) Treatment of ocular neovascularization and related diseases
EP1455780A4 (en) Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU4114301A (en) Treatment of ocular hypertension and glaucoma
AU2002246521A1 (en) Topography-guided opthalmic ablation and eye-tracking
AU5261898A (en) Tgfalpha for the treatment of ocular hypertension and glaucoma
NO20035043D0 (en) Procedure for the treatment of ocular hypertension and glaucoma
AU2000275035A1 (en) Therapeutic and prophylactic drugs of myopia
AU2001216038A1 (en) Treatment of glaucoma and ocular hypertension
IL152782A0 (en) S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002361516A1 (en) Ophthalmic rofecoxib suspension for the treatment of ocular pain and inflammation
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001270642A1 (en) Method for the treatment of glaucoma and ocular hypertension by administering nucleotides